Home - www.pronexus.se
Search - www.pronexus.se
Home Japan - www.pronexus.se


March, 2021, Sweden.  Pronexus received a second project funding from the Eurostars programme

We are proud to announce that Pronexus as a partner with the biotech startup company Synendos Therapeutics AG and three other partners received funding from the EU call Eurostars-2, for the project named E! 114985: EndoCARE: Restoring endocannabinoid homeostasis to create the first effective & safe pharmacotherapy for PTSD. Among 571 applications submitted, EndoCARE project was ranked at position 58 (number 13 among 88 Swedish applications) with a total score of 468 points (78%) of 600.

EndoCARE aims to develop the first effective and safe pharmacotherapy for post-traumatic stress disorder (PTSD). As many as 20 million people in EU/US suffer from extreme fear, flashbacks, nightmares and intrusive thoughts as a consequence of experiencing a traumatic incident. Yet, no effective treatment exists for these PTSD patients. Disruption of the endocannabinoid system is a key factor in PTSD and represents a novel target to develop effective treatments. EndoCARE aims to expand proof-of-mechanism in preclinical studies of Synendos´unique selective endocannabinoid reuptake inhibitor, SYT-510 featuring a novel mode of action to restore the physiological homeostasis of the endocannabinoid system.

The role of Pronexus in the project is to measure SYT-510 and the selected biomarkers of the endocannabinoid system in the rat brain, plasma and CSF samples in order to provide neurochemical correlates with in vivo effects in a rodent model of PTSD. We will apply the UHPLC-MS/MS methods for quantification of major endocannabinoids (AEA, 2-AG, 1-AG) and related endogenous molecules including arachidonic acid, N-acyl ethanolamines, prostaglandins and stress hormones, as well as the levels of SYT-510 in these samples. The second UHPLC-MS/MS method will be used to measure the major monoamine- and amino acid-neurotransmitters: dopamine, noradrenaline, 5-HT, histamine, glutamate and GABA in the samples dissected from the brain areas anatomically relevant to the pathophysiology of PTSD.

The goal of the EndoCARE project is to provide preclinical evidence for the efficacy of SYT-510 in the rat PTSD model, and expand proof-of-mechanism studies on the mode of action of SYT-510, enabling a translational preclinical package to derisk the planned clinical programme. The total two-years project budget equals ~€2.7M, of which ~€1.3M was earmarked from the Eurostars programme and ~€1.4M will be co-financed by the consortium.

September, 2020, Sweden. Pronexus ranked #3 for a project funding from the Eurostars programme

We are proud to announce that Pronexus as a partner with the drug discovery company Abfero Ltd. and two university partners have been approved funding for the project application E! 114370: PD-IRONSYN from the EU call Eurostars-2. Among more than 400 applications submitted, the PD-IRONSYN was ranked at position 3 (number 1 among 94 Swedish applications) with a total score of 547 points (91,2%) of 600, threshold 402 points.

The objective of the project is to obtain preclinical proof-of-performance for a first-in-class, non-toxic iron chelating compound as a disease-modifying therapy for Parkinson’s disease (PD). PD affects about 1.2 million Europeans, a number that is expected to double by 2050. The main applicant Abfero has developed SP-420, a novel iron chelator that aims to prevent the accumulation of iron ions in the brain in order to reduce iron-related oxidative stress, cell death (ferroptosis) and alpha synuclein aggregation, well known neuropathological hallmarks of PD.

Pronexus will carry out PK/PD studies to establish the targeted bioavailability of SP-420 and its analogues in the brain by use of microdialysis and to measure the PK profiles of SP-420 and the potential metabolites by liquid chromatography tandem mass spectrometry (LC-MS/MS). Another aim of this task will be to develop and validate the LC-MS/MS methods which will fulfil the FDA and EMA guidelines for bioanalytical method validation acceptable for analysis of clinical samples.

The final goal of the PD-IRONSYN project is to deliver the preclinical data for the efficacy of the SP-420 iron chelator, which will be sufficient to initiate the subsequent clinical trials.The total 3-years project costs equal ~€1.98M, of which ~€1.02M was earmarked from the Eurostars programme and ~€0.96M will be co-financed by the consortium.

April,2020, Sweden. Pronexus fully complieswith regulations for social distancing dueto the Covid-19 pandemy,but we operate, although on a reduced scale. 

Read the latest publication from a collaborative study between QPS Austria and Pronexus: “Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease”, Victoria Schiffer, Estibaliz Santiago-Mujika, Stefanie Flunkert, Staffan Schmidt, Martina Farcher, Tina Loeffler, Irene Schilcher, Maria Posch, Joerg Neddens, Ying Sun, Jan Kehr, and Birgit Hutter-Paier.PLoSONE 15(1): e0227077. https://doi. org/10.1371/journal.pone.0227077

October 19-23,2019, Chicago, IL, USA. Society for Neuroscience, booth #1466

Pronexus Analytical exhibited (booth #1466) at the Neuroscience 2019 meeting in Chicago. Pronexus in a joint partnership with QPS Neuro (booth #1464) offer a broad suite of services in preclinical research and drug discovery. We welcome our existing and potential new clients to contact us to discuss your specific needs and requirements for functional evaluation of your test compounds in disease models.

November 4-7,2018, San Diego, CA, USA. Society for Neuroscience, booth #3012

Pronexus Analytical exhibited (booth #3012) at the Neuroscience meeting in San Diego. Pronexus in a joint partnership with QPS Neuro (booth #3014) offer a broad suite of services in preclinical research and drug discovery. The effects of test compounds can now be evaluated from the initial in vitro screening tests to in vivo studies in rodent models of psychiatric, neurodegenerative, rare diseases and metabolic disorders by implementing molecular, immunohistochemical, neurochemical and behavioral techniques.

March 25-28, 2018, Oxford, UK. Monitoring Molecules in Neuroscience: 17th International Conference

Pronexus together with Allergan presented a poster: Rapastinel antidepressant-like activity is independent of increased efflux of dopamine, 5-HT and glutamate as observed for S-(+)-ketamine in the rat mPFC.

February 6, 2018, Stockholm (Sweden), Graz (Austria). Announcement - joint partnership

QPS Neuro and Pronexus announced formation of a joint partnership aiming to build their respective areas of expertise on unified experimental platforms and offer a broader suite of services to their clients. The effects of test compounds can be now evaluated from in vitro screening tests in cell cultures to in vivo studies in rodent models of psychiatric, neurodegenerative, rare disease and metabolic disorders and implementing molecular, immunohistochemical, neurochemical and behavioral techniques.

QPS Neuro (www.qpsneuro.com) is the Austria based early development site of QPS Holdings, LLC, a leading full-service contract research organization and has developed its reputation over the past three decades as a specialist in CNS and Orphan diseases including Alzheimer's and Parkinson's disease as well as HD, NPC, ALS, depression, psychosis and schizophrenia. QPS is a leading provider of genetically modified organisms for research in CNS diseases and able to combine behavioral analysis, neurochemistry and biochemistry as well as quantitative histology and histopathology. In addition, QPS Neuro has experience and access to unique biomarker technologies, owning, for example, the worldwide exclusive license to the A4-assay for A-beta oligomers from ProMIS Neurosciences.

We are all excited about this partnership with Pronexus Analytical, because it offers synergies for both partners. Our broad range of experience and theunique knowledge about our animal models, combined with the specific services available from Pronexus will help our clients to expedite new drug developments. Our future collaboration will afford market competitiveness, and allow us to remain the CNS specialist in early drug development” says Dr. Ben Chien, GM of QPS Austria GmbH and CEO of QPS Holdings, LLC.

Pronexus Analytical is a preclinical CRO offering advanced services in CNS pharmacology, neurochemistry and bioanalysis. Pronexus core expertise is focused on PK/PD studies using in vivo microdialysis, CSF, blood microsampling and brain microdissections. The bioanalytical services include UHPLC-MS/MS, UPLC-TOF, high-sensitive HPLC methods, and immunoassays for measuring the levels of neurotransmitters and other signaling molecules, metabolites, as well as concentrations of drugs and toxins in biological samples such as microdialysates, cell lysates, CSF, plasma, urine and tissue extracts.

I am delighted to be working with QPS Holdings, incorporating their renowned expertise in disease models”, said Dr. Jan Kehr, CEO of Pronexus Analytical AB, Sweden. “I believe the addition of Pronexus capabilities to monitor brain chemistry together with the QPS portfolio of behavioral tests and immunohistochemical assays will allow us to help our clients to better understand drug actions at a more detailed and quantitative level, and thereby improve predictability of efficacy and therapeutic utility of drug candidates in clinical trials”.

November 11-15, 2017, Washington, USA. Society for Neuroscience meeting

Pronexus exhibited at SfN 2017 conference, booth #139 presenting its recent portfolio of services including PK/PD studies on rodents and NHPs (in partnership with Pre-Clinical Research Center, UK, KY), proof-of-principle studies for candidate drugs implementing microdialysis, CSF and blood sampling. Pronexus bioanalytical services include UHPLC-MS/MS, UPLC-TOF and classical HPLC analysis of drugs, endogenous molecules such as neurotransmitters and metabolites, chiral separations and immunoassays. A small size of Pronexus company comprising a team of industry-experienced, PhD levels scientists offers highly interactive communication and flexibility in protocol design required particularly for exploratory studies, method development and collaboration with academia.

September 2-5, 2017, Paris, France. ECNP 2017

Pronexus participated at the 30th ECNP Congress (booth #12) to discuss our latest technologies and diseases models developed in collaboration with Pronexus partner Preclinical Research Center, Lexington, University of Kentucky. Pronexus and Preclinical Research Center together offer a broad suite of services from rodent models to NHPs on a unified experimental and bioanalytical platform.

July 16-20, 2017, London, UK. AAIC 2017

Pronexus participated at the 17th Alzheimer´s Association International Conference and presented the latest technologies and diseases models developed in collaboration with Pronexus partner Preclinical Research Center, Lexington, University of Kentucky. Pronexus and Preclinical Research Center together offer a broad suite of services from rodent models to NHPs on a unified experimental and bioanalytical platform.

March 29-April, 2017, Vienna, Austria. AD/PD 2017

Pronexus participated at the 13th International Conference on Alzheimer´s and Parkinson´s Diseases and discussed the latest analytical technologies, transgenic AD, PD mouse models and lesion (6-OHDA, MPTP, LPS) PD models in rats and mice developed at Pronexus.

December 4-8, 2016, Hollywood, Florida, USA. ACNP 55th Annual Meeting

Pronexus together with the sponsor company Allergan presented a poster at the ACNP meeting, 4-8 December 2016, Florida, USA, under a title: "Rapastinel(Glyx-13), a Rapid Acting Antidepressant, Does Not Increase ExtracellularLevels of Dopamine and Glutamate in Rat Medial Prefrontal Cortex". The presented data provide a potential neurochemical basis for rapastinel’s favorable CNS adverse effects compared to ketamine. Increase in brain dopamine and glutamate levels by ketamine may play a significant role in its high abuse potential and psychotomimetic-like effects.

November 12-16, 2016, San Diego, CA, USA. Society for Neuroscience, 46th Annual Meeting, booth #334

Pronexus Analytical exhibited at the SfN meeting in San Diego. We thank our existing and potential new clients for stopping by and discussing with us our latest portfolio of disease models and analytical services.

29 May – 2 June 2016, Gothenburg, Sweden. Monitoring Molecules in Neuroscience: 16th International Conference

Jan Kehr organized and chaired a session on “Monitoring neurotransmitters and related molecules in brain disorders”. The topics covered the use of microdialysis and biosensors in models of psychiatric and neurodegenerative disorders. The speakers and the titles of their presentations were:

1.Depression and mood disorders. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Connie Sánchez, Lundbeck Research, Denmark.

2. ADHD. Therapeutic Efficacy of Psychostimulants in ADHD: Preferential Targeting of Prefrontal Cortex Catecholamine Signaling. Craig Berridge, Psychology Department, Universityof Wisconsin-Madison, Madison, WI 53706, USA.

3. Schizophrenia. Evaluation of novel antipsychotic drug cariprazine compared to aripiprazole in rat PCP model of schizophrenia. Jan Kehr, Pronexus Analytical AB, Stockholm, Sweden.

4.Alzheimer´s disease. Using micro-immunoelectrodes to measure rapid amyloid-beta generation by synaptic activity in vivo. John R. Cirrito, Department of Neurology, Washington University, St. Louis, MO, USA.

5. Parkinson´s disease. Eltoprazine prevents levodopa-induced dyskinesia by reducing striatal glutamate and striato-nigral neuron activity. Michele Morari, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

April 4-6, 2016, Stockholm, Sweden

Pronexus attended the meeting BIO-EuropeSpring 2016 and presented its portfolio of services including disease models, proof-of-concept studies for neuropharmaceuticals, implementing Pronexus world leading expertise in microdialysis, neurochemical analysis and related bioanalytical services. A small size of Pronexus company comprising a team of industry-experienced, PhD levels scientists offers highly interactive communication and flexibility in protocol design required particularly for exploratory studies, method development and collaboration with academia.

August 26, 2015, Stockholm, Sweden

Pronexus is a partner in the EU-funded (H2020-PHC-2015) research project "Developing new therapies for Batten disease" (BATCure). The goal of the project is to advance the development of new therapeutic options for a group of rare diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. The NCLs are devastating and debiliating genetic disorders that mainly affect children, who suffer progressive dementia and motor decline, visual failure and epilepsy, leading to a long period of complete dependence on care givers, and eventually a premature death. There are no curative treatments in the clinic for any type of NCL. The project combines the expertise of recognized European research teams, both basic scientists and clinicians, high-technology SMEs and micro-SMEs, and an NCL patients’ organisation. This multidisciplinary and cross-sectoral, scientific and medical interactive European group aims to develop innovative therapies for Batten disease. Pronexus part will include neurochemical monitoring of new treatments on mouse models of Batten disease.

 October 1, 2013, Stockholm, Sweden

Pronexus becomes a partner in the EU-funded research project (EU-FP7-Health) HUMAN (Health and the Understanding of Metabolism, Aging and Nutrition). The objective of the project is to study the function of genetic risk variants associated to metabolic diseases with the use of mouse models with humanised liver and pancreas.
The HUMAN consortium associates a core of outstanding basic research institutions to leading European biotech SMEs taking advantage of both academic and SME partners who have the ad hoc facilities. The main goal of HUMAN is to offer European research and industries exclusive tools to tackle the challenge of functional validation of metabolic disease-associated genetic variants by offering: i) innovative and robust humanised animal and cellular models; ii) a portfolio of new and validated therapeutic targets for better understanding of metabolic diseases and healthy aging. HUMAN will generate iPSCs biobanks and comprehensively manage all associated information, including clinical and metabolic profiles of the donors, the phenotypes of iPSCs and of the different humanised mice, using state of the art technologies (proteomics, metabolomics, epigenomics, transcriptomics, glycomics). In sum, the HUMAN consortium is uniquely situated to drive innovation towards a better knowledge of the genetic basis of major human metabolic diseases, thereby contributing to the understanding of healthier aging of Europeancitizens.

September 16-20, 2012, London, UK. Monitoring Molecules in Neuroscience: 14th International Conference

Jan Kehr presented a lecture entitled "Use of microdialysis in translationa research", with coauthors Takashi Yoshitake from Karolinska Institutet, Stockholm, and Bengt Dahlström and Folke Sjöberg from CTC Clinical Trial Consultants in Uppsala, Sweden. Microdialysis, voltammetric and biosensor techniques undoubtedly became the most widespread in vivo monitoring technologies in experimental neuropharmacology and neuroscience. However, the invasive character of these methods confines their clinical applicability mostly to neuromonitoring in intensive care, open and reconstructive surgery or to the use of microdialysis in organs such as skin or skeletal muscles. The purpose of the current effort is to use skin and/or muscle microdialysis, which are equally applicable both on healthy animals and humans, for monitoring effects of locally administered test compounds on the biomarker molecules, which might be associated with common PNS and CNS pathways. This makes it possible to use microdialysis as a truly translational technique for evaluation of drug effects from animal to human - for vascular microdosing and phase I trials. A complete abstract can be found on the conference website www.monitoringmolecules.org.

November 12-16, 2011, Washington, DC, USA. Society for Neuroscience

Pronexus Analytical presented a poster (KK13; 689.22) on Tuesday, November 15, Hall A-C, 1.00pm -3.00pm, entitled: “Designer drug mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats".

November 13-17, 2010, San Diego, CA, USA. Society for Neuroscience 40th Annual Meeting

Pronexus Analytical together with a client company Schwabe, Germany presented a poster (#162.6) on Sunday, Nov. 14, 9:00-10:00, entitled: “Effects of intraperitoneal administration of Silexan, an essential oil from flowers of Lavandula angustifolia on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex of freely moving rats”. The microdialysis data support the clinically observed relaxing and anxiolytic actions of Silexan. During the last years, Pronexus scientists have carried-out several microdialysis and behavioral studies aiming to elucidate the mechanisms of action and the effects of herbal remedies, nutrients and thier active constituents on brain neurotransmission and metabolism.

September 12-16, 2010, Brussels, Belgium. Monitoring Molecules in Neuroscience. 13th International Conference on In Vivo Methods

Jan Kehr presented an opening Plenary Lecture entitled "Monitoring molecules in neuroscience: 50 years". The pdf version of this historical overview is available upon request. During the last 50 years, the development of techniques and methods for monitoring brain chemical signals, tissue metabolism and even targeted delivery and clearance of drugs and molecular labels have received considerable attention by scientific community, hospital care practitioners and manufacturers of medical devices. Current technologies for monitoring molecules or signals reflecting functional changes in brain chemistry include 1) minimally invasive techniques and 2) neuroimaging techniques. The techniques within the first group are widely used in experimental medicine and pharmacology, whereas neuroimaging techniques have been established predominantly in clinical neuroradiology. There is a great potential for further development and new applications of microdialysis and biosensor technologies as the key techniques in pharmacological neurochemistry in vivo and in studies on neurochemical basis of behavior. Further advancements in development of less invasive, more specific and sensitive devices and methods are warranted and expected to strengthen the use of in vivo monitoring techniques in functional pharmacology and enabling more efficient searching for novel biomarkers of CNS diseases.

May 27,2010 Lyon, France. In vivo Neurochemistry Symposium

Dr. Jan Kehr, CEO of Pronexus Analytical and the senior scientist at Karolinska Institutet, Stockholm, Sweden was invited to the Sympoisium on In vivo Neurochemistry to be held in Lyon on May 27 and give a lecture entitled: “Monitoring brain neurotransmission and metabolism by in vivo microdialysis: A historical overview and future perspectives”. For information on the conference, please contact Dr. Luc Denoroy at luc.denoroy@recherche.univ-lyon 1.fr

October 30, 2009, Stockholm. Pronexus Analytical exhibited at the Society for Neuroscience 39th Annual Meeting in Chicago, IL, USA, Oct 17-21, 2009, booth #1714

Thank you for stopping by at the Pronexus booth and discussing the implications of techniques and services offered by Pronexus for your particular projects and research interests. Pronexus main focus is currently given to the development and applications of protocols and methods enabling fast in vivo neurochemicasl screening for evaluation of lead compounds and candidate drugs in experimental disease models. In addition, Pronexus together with its partner Quanteon LLC exhibited the instruments and devices for in vivo biosensor monitoring. This unique technology allows second-by-second recordings of extracellular levels of glutamate, acetylcholine, dopamine and other neuroactive molecules in the brains of awake or anaesthetized animals, as well as in brain slices.

Pronexus together with colleagues from Karolinska Institutet presented a poster (#729.12) entitled: The selective 5-HT1A receptor antagonist NAD-299 increases acetylcholine but not glutamate levels in the frontal cortex and hippocampus of awake rat. (Poster session 729, Alzheimer´s disease: Animal Models and Therapeutic Intervention, South Hall A, Wednesday, October 21, 2009, 8:00 AM-12.00 PM).

July 1, 2009, Stockholm-Bromma Pronexus moves to new laboratories

Pronexus Analytical is proud to announce that from July 1st, the company has moved to a new facility in Bromma, west Stockholm. The company´s total area of 220 sqm includes the GLP-compliant bioanalytical laboratory and the animal research facility with full regulatory approvals. Pronexus is privately owned and independent SME, yet in close association and proximity to Karolinska Institutet. Furher, Pronexus in the only small enterprise among the life science companies in the Stockholm region, which is offering experiemntal services on CNS disease models. We invite proposals on partnership formations, collaborative studies, as well as on sub-contracting opportunities both with the industry and academic institutions.

April 1, 2009, Stockholm Kent Jardemark, PhD, assoc. prof., joins Pronexus

Pronexus Analytical is expanding its range of services in preclinical neuropharmacology by introducing the electrophysiological techniques to its suite of in vivo monitoring methods. From April 1st, Dr. Kent Jardemark has joined the Pronexus team. Dr. Jardemark comes from the Department of Physiology and Pharmacology, Karolinska Institutet where he holds a position of associate professor in neuropsychopharmacology. Kent has more than 20 years of experience with electrophysiological recordings of brain activity, particularly in research focused on studying the effects of antipsychotic drugs and drugs of abuse.

February 5, 2009, Karolinska Institutet, Stockholm. Scanbur Seminar 

Jan Kehr presented a lecture entitled "Monitoring neurotransmitters by microdialysis and biosensors in awake rats and mice".

August 10-14, 2008, Vancouver, BC, Canada.Monitoring Molecules in Neuroscience. 12th International Conference on In Vivo Methods

The 12th conference on In vivo methods was strongly represented by the contributions demonstrating the feasibility of biosensor technology for monitoring basal and stimulated neurotransmitter release and reuptake. The group of Prof. Gerhardt at University of Kentucky and the group of Dr. Kehr at Karolinska Institutet, Stockholm presented together 17 posters. In addition, there were several oral presentations and plenary lectures given by the leaders in the field of in vivo voltammetry. 
Some of the major achievements are summarized below:
Glutamate biosensor
Sensors cause a minimal damage to the brain tissue, which enables to use them for repeated monitoring over several days Basal Glu levels are TTX-sensitive and calcium dependent
There are age-dependent differences in Glu basal levels, stimulated release and reuptake in various rat brain regions
Glu levels can be monitored for up to seven days in the striatum or PFC of awake mice
Cortical Glu levels are increased in pain (formalin model) and are reduced after gabapentin
mGluR2/3 agonist LY379268 attenuated potassium-induced Glu release in the rat PFC
Increase in Glu levels was monitored in the rat striatum up to 48 h after the traumatic brain injury
Acetylcholine biosensor
Recombinant human acetylcholinesterase improved the sensitivity of the ACh /Ch biosensor
Dopamine biosensor
Amperometric biosensor coated withm-phenylenediamine (mPD) was specific and sensitive to detect basal and amphetamione-stimulated DA levels in the rat striatum. 

Nov 12-14th, 2007 Minneapolis, Minnesota, USA
Frontiers in Proteomics and Nanomedicine
Dr. Jan Kehr, one of the organizers of the symposium arranged by University of Minnesota, Mayo Clinic and Karolinska Institutet presented a lecture entitled "Nanomaterials for In Vivo Monitoring and Imaging", focusing on applications of microsystems and nanomaterials for microdialysis, biosensors and MRI techniques in experimental neuropharmacology.

Oct 6-7th, 2007 Seoul, Korea
3rd Symposium on Acupuncture & Meridian Studies

Dr. Jan Kehr, was invited to participate at the 3rd Symposium on Acupuncture & Meridian Studies, organized by the Society for Meridian & Acupoint, Korean Pharmacopuncture Institute and Acupuncture & Meridian Science Research Center, Seoul, Korea. The title of Dr. Kehr´s lecture was " Use of microdialysis for monitoring chemical signals in vivo: Implications in acupuncture research".

Sept 19-21, 2007 Cambridge, UK
The 4th International Conference on Clinical Microdialysis
Dr. Jan Kehr, CEO of Pronexus Analytical and the senior scientist at Karolinska Institute was invited to participate at the International Conference on Clinical Microdialysis and give two oral presentations entitled:
"Analytical techniques for Microdialysis samples" at the first conference session on Advances in Clinical Microdialysis. The second lecture
"Methodological considerations when designing and using microdialysis catheters for drug recovery" was presented in the session Monitoring drugs and drug distribution.
For information on the conference proceedings contact Mrs. Ulla Ungerstedt (ulla.ungerstedt@microdialysis,se) at CMA Microdialysis, Stockholm.

May 30 - June 2, 2007 Göteborg, Sweden
Dopamine 50 years
This symposium was organized in honour to Prof. Arvid Carlsson for his discovery of neurotransmitter dopamine in 1957. For this discovery, Prof. Carlsson won the Nobel price in medicine in 2000. Dr. Jan Kehr from the Department of physiology and pharmacology, Karolinska Institutet, Stockholm and Dr. Pia Weikop from NeuroSearch A/S, Ballerup, Denmark presented a poster entitled: "Triple-acting monoamine reuptake inhibitors: Role of dopamine in augmentation strategies for antidepressant drugs". This presentation summarized the results of the
Dr. Weikop´s thesis and the related papers recently published by these authors.

Aug 29 - Sept 2, 2006, Helsinki, Finland
International Congress and 54th Annual Meeting of the Society for Medicinal Plant Research
Dr. Jan Kehr from Pronexus Analytical was invited to present the results of the studies "Effects of acute and repeated administration of Hypericum perforatum extract (WS 5572®) and its main constituents on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain: A microdialysis study" (oral presentation) and " Effects of chronic administration of Ginkgo biloba extract (EGb 761®) on levels of dopamine, noradrenaline and serotonin in the prefrontal cortex of the awake rat" (poster). Both studies were sponsored by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.

May 19-22, 2006 Villasimius, Sardinia, Italy
Monitoring Molecules in Neuroscience. 11th International Conference on In Vivo Methods

Dr. J. Kehr and Dr. D. Scheller from Schwarz Biosciences, Monheim, Germany presented a poster entitled "Evidence for Continuous Dopamine Receptor Stimulation by Rotigotine in Freely Moving Rats". Rotigotine is a non-ergolinic dopamine agonist, which was developed as a patch for therapy of Parkinson’s disease. The study was designed to evaluate whether the continuous administration of rotigotine mediates a continuous stimulation of dopamine receptors.

April 27, 2006 Suwon, Korea
International Symposium on Advanced Nanodevices Technology

At the occasion of the inauguration of Korea Advanced Nano Fab Center (KANC), Dr. Kehr was an invited speaker with a lecture entitled
"Nanotechnology in drug discovery: focus on in vivo monitoring and imaging techniques". The lecture gave an overview on the state-of-the-art in the field of imaging and monitoring techniques with focus on applications in neuroscience and neuropharmacology.

Dec 19th, 2005 Stockholm Sweden
CMA Microdialysis and Pronexus Analytical form strategic partnership to offer Microdialysis contract research services

Pronexus Analytical AB is a contract research organization offering services to pharmaceutical companies and research institutions active within the therapeutic area of diseases affecting the central nervous system. CMA Microdialysis AB is the leader in the development, manufacturing and marketing of Microdialysis products for scientific research and clinical diagnostics.

Through the partnership, CMA and Pronexus can enable in vivo Microdialysis and allied analytical techniques to accelerate the process of drug discovery, particularly in its late phase strengthening the functional validation of candidate drugs.

 “By combining high-quality products, excellent competencies and very strong analytical skills, the partnership offers unique outsourced services to the drug industry which is requiring faster and more cost-effective throughput,” said Philip Siberg, CEO of CMA Microdialysis AB.

According to Jan Kehr, CEO of Pronexus Analytical AB: “Microdialysis is a key technology that provides the closest correlation of in vivo neurochemical data to behavioural or electrophysiological measures of brain activity. Microdialysis data can play a crucial role in decision process concerning the preclinical and clinical development phases of new drugs”.

For more information contact:
Bodil Käller, Sales & Marketing Manager Preclinical Products CMA Sweden
Tel: +46 8 470 1070 bodil.kaller@microdialysis.se

Kathleen Gariepy, Product & Marketing Manager CMA USA
Tel: +1 800 440 4980 kathleen.gariepy@microdialysis.com

Jan Kehr, PhD, CEO Pronexus Analytical
Tel: +46 70 796 2606 jk@pronexus.se

About Pronexus Analytical:
Pronexus Analytical AB is a newly established spin-off company from the Karolinska Institutet and linked to the Karolinska Science Park in Stockholm. The staff scientists at Pronexus Analytical possess a unique combination of expertise and skills in Microdialysis, microsurgery and in vivo handling protocols for small rodents, neurochemical analysis, especially in high-sensitive HPLC techniques for determination of neurotransmitters, as well as, knowledge in neuroanatomy and neuropharmacology of major transmitter systems. Pronexus has all the required ethical and regulatory approvals for small animal research and is based in Sollentuna, Sweden.

About CMA Microdialysis:
CMA was formed in 1984 and was the first company in the world to market Microdialysis products and know-how. Consumables, instruments and software are sold to universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling of organs and tissues. CMA has its HQ in Sweden with subsidiaries in Germany and USA.

Oct 1-4, 2005, Ischia, Italy
National Congress of the Italian Society for Neuroscience and Joint Italian-Swedish Neuroscience Meeting
Jan Kehr was an invited speaker at this joined Italian-Swedish neuroscience conference. In his presentation "Advances in analytical techniques for microdialysis", Dr. Kehr provided a summary on recent development of high sensitive derivatization techniques for HPLC determination of classical neurotransmitters in the microdialysates, plasma and other body fluids or tissue extracts.

June 24-27, 2003 Karolinska Institutet, Stockholm, Sweden
Monitoring Molecules in Neuroscience. The 10th International Conference on In Vivo Methods
Dedicated to memory of Prof. Ralph N. Adams

Dr. Jan Kehr with his colleagues at Karolinska Intitutet organized The 10th International Conference on In Vivo Methods. Pronexus Analytical AB together with Quanteon LLC, presented the Fast Analytical Sensor Technology (FAST), particularly the new FAST 16-mkI amplifier unit and the multi-site microelectrodes for rapid monitoring of glutamate release. The Proceedings book was edited by Jan Kehr, Kjell Fuxe, Urban Ungerstedt and Torgny H. Svensson.

For further information on the Proceeding book, contact Jan Kehr (jk@pronexus.se).